Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; ho...

Full description

Bibliographic Details
Main Authors: Ágnes Milassin, Anna Fábián, Tamás Molnár
Format: Article
Language:English
Published: SAGE Publishing 2019-04-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284819842748